GLA-LSQ

BIOLOGICAL2 trials

Sponsors

University Hospital Tuebingen, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsMalaria, Antepartum

Phase 1

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

CompletedNCT02647489

University Hospital TuebingenMalaria, Antepartum

Start: 2016-05-31End: 2017-11-10Updated: 2018-06-26

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

CompletedNCT04177355

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2020-01-13End: 2024-11-04Updated: 2025-09-02

Related Papers

Progress and Insights Toward an Effective Placental Malaria Vaccine.

2021-02-2529 citations

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Clinical Infectious Diseases2019-01-03150 citations

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.

2017-01-2512 citations